olmesartan has been researched along with ethinyl estradiol in 4 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (ethinyl estradiol) | Trials (ethinyl estradiol) | Recent Studies (post-2010) (ethinyl estradiol) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 9,070 | 1,566 | 1,732 |
| Protein | Taxonomy | olmesartan (IC50) | ethinyl estradiol (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.2 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Estrogen receptor | Homo sapiens (human) | 0.0035 | |
| Glucocorticoid receptor | Homo sapiens (human) | 1.71 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.71 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.959 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 5.678 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 4.8812 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.71 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.71 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.959 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.71 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.054 | |
| Sulfotransferase 1A1 | Homo sapiens (human) | 0.02 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.559 | |
| Aldehyde oxidase | Homo sapiens (human) | 0.57 | |
| Nuclear receptor subfamily 1 group I member 3 | Homo sapiens (human) | 3 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0129 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
4 other study(ies) available for olmesartan and ethinyl estradiol
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |